World’s First End-to-End IoT Subscription Service for Remote Monitoring Launched by Hiber With Oil & Gas Well Integrity Monitoring to Prevent Leakage & Build a More Sustainable Practice
Dutch satellite Internet-of-Things (IoT) solution startup, Hiber, today announces the launch of HiberHilo, its first end-to-end solution for Oil & Gas Well Integrity Monitoring. HiberHilo is also the world’s first subscription service for IoT-enabled remote Oil/Gas Well monitoring and the company will be introducing similar services for other specific use cases in 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005336/en/
HiberHilo Dashboard (Photo: Business Wire)
There is a growing demand for remote monitoring in industries such as Oil & Gas to create more sustainable and environmentally friendly practices, especially with COVID-19 limiting travel halting routine maintenance checks. However, the IoT SaaS market in this space is nascent and lacks simplicity. Having already been one of the first firms to develop a remote IoT connectivity solution with the launch of its proprietary nano-satellites in 2018, Hiber identified the urgent need for readily available out-the-box end-to-end subscription based offerings. These must be designed bespoke for particular use cases, as well as being simple and efficient for businesses to install and implement.
The HiberHilo solution for Oil & Gas Well Integrity Monitoring is the first offering of this kind that Hiber will launch because this process is currently complex, time-consuming and expensive (costing up to $40,000 per field visit). Additionally, manual monitoring is prone to error and is often not conducted frequently enough.
Monitoring is critical to ensure that anomalies are identified early and addressed - this can include potential leaks which, if left unaddressed, can impact people’s health and safety as well as negatively impact the environment. HiberHilo’s out-of-the-box subscription solution utilises Hiber’s global satellite network to empower organisations to automate continuous annulus pressure and wellhead monitoring of up to 250 wells in a radius of 10km, even in the most remote locations on Earth. Pricing starts at $449 per month per well (1 sensor and a 5 year contract).
The all-in-one product is available as both a starter kit and in the form of an enterprise solution, both of which feature:
- A pressure and optional temperature sensor to ensure accurate and regular measurements - organisations can add more sensors to the network if required
- Easy connectivity anywhere, sending up to 24 messages a day or one per hour
- Alarm and alert settings
- An intuitive dashboard for desktop and mobile
- Support both on-site and via mobile
Coen Janssen, co-founder and Chief Strategy Officer at Hiber said, “We are excited to launch this first-of-its-kind IoT proposition for remote monitoring at a time when it is needed more than ever. HiberHilo has already been proven by Nederlandse Aardolie Maatschappij (NAM) and Royal Dutch Shell (better known as just “Shell”) on an abandoned on-shore well. This technology can be installed in less than 2 hours and within 0.25% accuracy levels of a traditional wired system, which is extremely reliable.”
“We look forward to more companies embracing this new proposition as it will save them time, money and lives by allowing teams to monitor well integrity from home as well as reducing the risk of well integrity issues to create more sustainable practices. The future for remote monitoring is very bright!”
Hiber entered the market in 2018 purely as a connectivity provider, utilising its own proprietary nano-satellite technology to unlock IoT connectivity in the 90% of the world without it. For more information on HiberHilo visit: hiberhilo.com or watch this video.
-- ENDS --
About Hiber
Hiber is an Internet of Things (IoT) solution startup, founded and led by a dream team of satellite experts and tech entrepreneurs. These 'Hibernauts' are working on a moonshoot goal: to launch and provide end-to-end IoT solutions connected by satellites in space. More than 55 employees work on the ground-breaking technology behind Hiber and Hiberband at its offices in the Netherlands and USA.
To date, the company has managed to attract significant funding. This has meant that in November 2018 Hiber became the Netherlands’ first commercial satellite company, launching its first two nano-satellites into orbit. Hiber officially launched at the Amazon Web Services’ (AWS) Re:invent Conference in November 2018 where they were named Commercial Startup Launch of 2018 at the AWS conference.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005336/en/
Contact information
Jasper Fassaert
pr@hiber.global
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
